Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Sponsor: Nanfang Hospital, Southern Medical University
Summary
For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early , and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate.Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer.
Official title: Efficacy and Safety of Neoadjuvant Cadonilimab and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Prospective, Open-label, Single-Arm Phase II Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-03
Completion Date
2028-03
Last Updated
2024-03-15
Healthy Volunteers
No
Interventions
Cadonilimab
10mg/kg intravenous (IV) every 3 weeks ;
Oxaliplatin
130mg/m², iv drip for 2h, d1, q3w;
Capecitabine
1000mg/m² po, Bid, d1-14, q3w ;
Locations (1)
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China